This article was originally published in The Gray Sheet
Files 510(k) application for its QuickVue one-step fecal occult blood test. Quidel maintains that the two-minute test has "improved specificity and sensitivity over the most widely used tests which employ guaiac-based chemistry." Accuracy of guaiac-based tests is affected by patient noncompliance with dietary restrictions that must be followed for two days prior to testing. "The QuickVue FOB test circumvents the dietary restrictions and compliance problems...because it is very specific for human hemoglobin found only in human red blood cells," Quidel says.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.